Shanghai Fudan Forward S&T Co., Ltd

SHSE:600624 Rapporto sulle azioni

Cap. di mercato: CN¥3.9b

Shanghai Fudan Forward S&T Performance dei guadagni passati

Il passato criteri di controllo 0/6

Shanghai Fudan Forward S&T's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 13.9% per year.

Informazioni chiave

-19.8%

Tasso di crescita degli utili

-20.0%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore10.9%
Tasso di crescita dei ricavi-13.9%
Rendimento del capitale proprio-4.3%
Margine netto-5.3%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Solid Earnings May Not Tell The Whole Story For Shanghai Fudan Forward S&T (SHSE:600624)

Sep 06
Solid Earnings May Not Tell The Whole Story For Shanghai Fudan Forward S&T (SHSE:600624)

Recent updates

What Shanghai Fudan Forward S&T Co., Ltd's (SHSE:600624) 33% Share Price Gain Is Not Telling You

Oct 01
What Shanghai Fudan Forward S&T Co., Ltd's (SHSE:600624) 33% Share Price Gain Is Not Telling You

Solid Earnings May Not Tell The Whole Story For Shanghai Fudan Forward S&T (SHSE:600624)

Sep 06
Solid Earnings May Not Tell The Whole Story For Shanghai Fudan Forward S&T (SHSE:600624)

What Shanghai Fudan Forward S&T Co., Ltd's (SHSE:600624) 32% Share Price Gain Is Not Telling You

Jul 24
What Shanghai Fudan Forward S&T Co., Ltd's (SHSE:600624) 32% Share Price Gain Is Not Telling You

Some Confidence Is Lacking In Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) As Shares Slide 29%

Jun 06
Some Confidence Is Lacking In Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) As Shares Slide 29%

Shanghai Fudan Forward S&T Co., Ltd's (SHSE:600624) Share Price Could Signal Some Risk

Feb 27
Shanghai Fudan Forward S&T Co., Ltd's (SHSE:600624) Share Price Could Signal Some Risk

Ripartizione dei ricavi e delle spese

Come Shanghai Fudan Forward S&T guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

SHSE:600624 Ricavi, spese e utili (CNY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 24639-3423933
30 Jun 24649-1125231
31 Mar 24665-526434
31 Dec 23680626335
30 Sep 23731-326237
30 Jun 23765-926639
31 Mar 23741-1225339
31 Dec 22789-626940
30 Sep 22837-11828241
30 Jun 22919-11029042
31 Mar 221,011-10431649
31 Dec 211,041-10533149
30 Sep 211,005-6832250
30 Jun 21994-6233354
31 Mar 21979-6832948
31 Dec 20940-6031451
30 Sep 209753833160
30 Jun 209863735858
31 Mar 201,1005439857
31 Dec 191,4005643753
30 Sep 191,4125245846
30 Jun 191,4065247642
31 Mar 191,2874846744
31 Dec 181,0084345041
30 Sep 189314842734
30 Jun 188544433852
31 Mar 187984327940
31 Dec 177364222833
30 Sep 177102819326
30 Jun 17701331870
31 Mar 17687401800
31 Dec 16671381770
30 Sep 16691601690
30 Jun 16676571700
31 Mar 16676531620
31 Dec 15718521560
30 Sep 15809441550
30 Jun 15891421500
31 Mar 15975411590
31 Dec 141,008411540
30 Sep 14985361460
30 Jun 14987351320
31 Mar 14957341160
31 Dec 13952341120

Guadagni di qualità: 600624 is currently unprofitable.

Margine di profitto in crescita: 600624 is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 600624 is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.

Accelerare la crescita: Unable to compare 600624's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: 600624 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).


Rendimento del capitale proprio

ROE elevato: 600624 has a negative Return on Equity (-4.33%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate